Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
51.40
+0.25 (0.49%)
At close: Dec 20, 2024, 4:00 PM
52.55
+1.15 (2.24%)
After-hours: Dec 20, 2024, 4:24 PM EST
Corcept Therapeutics Employees
Corcept Therapeutics had 352 employees as of December 31, 2023. The number of employees increased by 53 or 17.73% compared to the previous year.
Employees
352
Change (1Y)
53
Growth (1Y)
17.73%
Revenue / Employee
$1,785,668
Profits / Employee
$399,111
Market Cap
5.39B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
RadNet | 8,441 |
Merit Medical Systems | 6,950 |
Stevanato Group | 5,634 |
Alkermes | 2,100 |
Tempus AI | 1,952 |
Inspire Medical Systems | 1,011 |
Ionis Pharmaceuticals | 927 |
BridgeBio Pharma | 556 |
CORT News
- 5 days ago - Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - Business Wire
- 9 days ago - Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes - Business Wire
- 10 days ago - Corcept Therapeutics' ALS drug fails in mid-stage trial - Reuters
- 10 days ago - Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 24 days ago - Corcept Therapeutics: A Most Promising And Compelling Biotech - Seeking Alpha
- 7 weeks ago - Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update - Business Wire
- 2 months ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire